Target intelligence / Profile preview

Lactate dehydrogenase of Streptococcus mutans (LDH)

Target
LDH
Molecular classification
Enzyme, Oxidoreductase, Bacterial virulence factor
01

Overview

Lactate dehydrogenase of Streptococcus mutans is a cytoplasmic enzyme (EC 1.1.1.27) crucial for the fermentation pathway, catalyzing the reduction of pyruvate to lactate using NADH as a cofactor and thus regenerating NAD+ for continued glycolysis[3][7]. The enzyme is allosterically activated by fructose-1,6-bisphosphate and is a central determinant of S. mutans acidogenicity, contributing directly to dental caries pathogenesis by increasing local acidification and enamel demineralization[3][4][6]. LDH is considered a key virulence factor; mutants deficient in LDH show severely diminished cariogenic ability and can even outcompete wild-type strains in plaque formation but with reduced acid production and caries potential[5]. The enzyme is subject to post-translational regulation such as lysine acetylation (negatively regulating its activity), underscoring its essentiality in metabolic adaptation and virulence expression in response to environmental cues[1][2].

Other names
S. mutans LDHL-lactate dehydrogenase (EC 1.1.1.27)
02

Mechanism of action

Enzyme inhibitors (decrease LDH activity to reduce lactic acid production, thus decreasing virulence/cariogenicity of S. mutans)[1]. Allosteric regulators (e.g., fructose-1,6-bisphosphate serves as an allosteric activator, required for maximal enzymatic activity)[3][6][7].

03

Biological functions

Catalysis of pyruvate to lactate (lactic acid production)Regeneration of NAD+ from NADHFermentation (specifically, pyruvate fermentation to lactate)Acidogenicity (generation of acid from carbohydrate metabolism)Virulence factor (contributes to cariogenicity)
04

Disease associations

Infection (oral/dental; specifically dental caries/cavities)Other (contributor to aciduricity and biofilm formation)
05

Safety considerations

Inhibition of S. mutans LDH is not known to cause systemic toxicity in humans, but selective targeting without disturbing host or commensal flora remains a challenge[1][3].
06

Interacting drugs

No clinically used drugs are directly reported to target S. mutans LDH as of current literature; experimental inhibitors aimed at decreasing cariogenicity have been studied but no approved therapies exist[1][3][5].

1 more in the full profile.

07

Biomarkers

LDH activity or expression can be used experimentally as a biomarker of S. mutans metabolic state and virulence, but is not clinically standardized[1][4][6].

Beyond the preview

Go deeper on Lactate dehydrogenase of Streptococcus mutans (LDH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactate dehydrogenase of Streptococcus mutans (LDH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call